We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Monoclonal antibodies (mAb) are approved in a wide range of conditions and represent the largest class of biotherapeutic products. mAbs are large molecules with complex structures and functions.
Inhibrx announced dosing has begun in a Phase 1 dose-escalation clinical trial of INBRX-105. INBRX-105 is a novel, multispecific antibody therapeutic candidate that is both an antagonist of PD-L1 and .....